Aegerion Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 92   

Articles published

AEGR 27.20 +0.20 (0.74%)
price chart
Aegerion Pharmaceuticals Observes Rare Disease Day
CAMBRIDGE, Mass., Feb. 28, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating rare ...
Why Aegerion Pharmaceuticals, Inc. Stock Collapsed in October
What: Shares of Aegerion Pharmaceuticals (NASDAQ: AEGR ) , a biopharmaceutical company focused on developing drugs to treat rare diseases, collapsed in October and lost 40% of their value, based on data from S&P Capital IQ, after the company ...
Aegerion Pharmaceuticals Acquires Myalept(TM) From AstraZeneca  GlobeNewswire (press release)
Aegerion Pharma Buys Drug From AstraZeneca for $325M  Mergers & Acquisitions - The Middle Market
Related articles »  
Aegerion Pharmaceuticals, Inc. Soars After Sarissa Capital Discloses Stake
The shares of Aegerion Pharmaceuticals surged after Sarissa Capital Management disclosed its stake in the company. The stock was trading at $25.70 per share, up by more than 8% to $25.87 per share at the time of this writing around 2:33 in the ...
Activist Discloses 5.7% Stake In Aegerion Pharmaceuticals  Benzinga
Aegerion Pharmaceuticals, Inc. Receives Average Target Price of $39.29  Bar and Graph Report
Aegerion Pharmaceuticals Announces Fourth Quarter and Full Year 2014 ...
CAMBRIDGE, Mass., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare ...
Aegerion Pharmaceuticals (AEGR) Announces Quarterly Earnings Results
Aegerion Pharmaceuticals logo Aegerion Pharmaceuticals (NASDAQ:AEGR) posted its quarterly earnings results on Thursday.
Aegerion Pharmaceuticals (AEGR) Releases Quarterly Earnings Results, Beats ...  The Legacy
Aegerion Pharmaceuticals Earns "Neutral" Rating from JPMorgan ...  sleekmoney
Share Price of Aegerion Pharmaceuticals, Inc. Drops by -2.73%
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) has dropped 2.73% during the past week, however, the bigger picture is still very bullish; the shares have posted positive gains of 10.31% in the past 4 weeks.
Aegerion Pharmaceuticals Given Consensus Recommendation of "Hold" ...  WKRB News
Perilous Reversal Stock: Aegerion Pharmaceuticals (AEGR)
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Trade-Ideas LLC identified Aegerion Pharmaceuticals ...
Stock in Focus : Aegerion Pharmaceuticals Inc (NASDAQ:AEGR)  Street Report
Aegerion Pharmaceuticals, Inc. Analyst Rating Update
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) has received a Neutral rating, according to the latest recommendation of 3 from research firm, Zacks.
Aegerion Pharmaceuticals Completes Acquisition of MYALEPT(R)
CAMBRIDGE, Mass., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) today announced that it has completed the acquisition of MYALEPT� (metreleptin) for injection, an orphan drug product that is indicated to treat ...
Report: Holders Push For Sale At Aegerion Pharmaceuticals  Benzinga
Aegerion Pharmaceuticals (AEGR) Is Today's Dead Cat Bounce Stock
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States.
Aegerion Downgraded As Stock Sheds 41% On Disappointing Q3 Results  Bidness ETC
Meet The Biopharma Stock That Lost 34% Last Week  Benzinga
Related articles »